Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Evox Therapeutics Ltd.

www.evoxtherapeutics.com

Latest From Evox Therapeutics Ltd.

Hijacking The Messenger

Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities. 

Innovation Research and Development Strategies

Mentioned In Despatches: Ablynx's Story From The Frontline Of The Biotech Boom

A little over 12 months ago, Belgian Nanobody biotech Ablynx was at the center of a bidding war between Novo Nordisk and Sanofi. Ex-Ablynx CEO Edwin Moses talked to Scrip about the four-month period that changed the course of the company.

M & A Leadership

Venture Funding Deals: Atreca Raises $125m To Advance Solid Tumor Candidate

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced August and September.

Deals Financing

Exosome Pioneer Evox's Series B Gives It Needed Financial Runway, CEO Says

Privately held Evox Therapeutics raised £35.5m ($45.4m) of new capital in a series B financing round, adding to the £10m injected by a series A seed financing a year ago.

Financing Commercial
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Site Specific
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Company Type
  • Start-Up
  • Parent & Subsidiaries
  • Evox Therapeutics Ltd.
  • Senior Management
  • Antonin "Tony" de Fougerolles, PhD, CEO
    Per Lundin, PhD, COO
  • Contact Info
  • Evox Therapeutics Ltd.
    Phone: (0) 1865 819140
    Oxford Science Park/Robert Robinson Ave.
    2nd Fl East Bld
    Oxford, OX4 4HG
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register